



IFW

Docket No.: 3493-0179PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bernard FREISS et al.

Application No.: 10/594,740

Confirmation No.: 5296

Filed: September 29, 2006

Art Unit: 1623

For: INCLUSION COMPLEXES CONTAINING
PIROXICAM, A CYCLODEXTRIN AND
ARGININE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL
REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE
1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

☒ a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

☐ b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

☐ c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s) and U.S. Filing Date

PCT/FR2005/000739 filed March 29, 2005

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

☐ a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

☒ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: an English language Abstract is provided for Croation Patent Application HR 200 10 543 A2. EP 0 524 632 A1 corresponds to SK 280 773B.

☒ c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

☐ d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

☐ a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

☐ b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

☐ c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*

☐ d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

☐ e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

☒ f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

☐ g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

☐ No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.
or

☐ See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

☐ b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

☐ d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

☐ The required fee is listed on the attached Fee Transmittal.


☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: FEB 02 2007

Respectfully submitted,

By 
MaryAnne Armstrong, Ph.D.
Registration No.: 40,069
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

- ☒ PTO-SB08
- ☒ Documents
- ☒ Foreign Search Report
- ☐ Fee
- ☐ Other:



Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/594,740
		Filing Date	September 29, 2006
		First Named Inventor	Bernard FREISS
		Art Unit	1623
		Examiner Name	Not Yet Assigned
Sheet	1	of	1
		Attorney Docket Number	3493-0179PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number-Kind Code ² (if known)				
/J.L.L./	BA	EP-0	991 407-B9	11-28-2001			
	BB	EP-1	018 340-A9	07-12-2000			
	BC	EP-0	449 167-A1	10-02-1991			
	BD	WO-02/32462-A1		04-25-2002			✓
	BE	EP-0	153 998-A2	09-11-1985			
	BF	WO-99/04765-A2		02-04-1999			
	BG	WO-03/030867-A2		04-17-2003			
	BH	EP-0	066 458-A1	12-08-1982			
	BI	EP-0	524 632-A1	01-27-1993			✓
/J.L.L./	BJ	SK-SR	280773-B	07-11-2000			✓

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/J.L.L./	CA	Redenti, E. et al.; J. of Pharmaceutical Sciences, Vol. 89, pp. 1-8 (2000).				
	CB	Buvani-Barcza et al., J. of Inclusion Phenomena and Macrocyclic Chemistry, Vol. 42, pp. 209-212 (2002).				
	CC	Mura, P. et al.; Journal of Inclusion Phenomena and Macrocyclic Chemistry, Vol. 39, pp. 131-138 (2001).				
	CD	Piel, G. et al.; Journal of Pharmaceutical Sciences, Vol. 86, No. 4, pp. 475-480 (1997).				
	CE	Fenivessy et al., Proceedings of the 7th Intl. Cyclodextrins Symposium, pp. 414-418 (1994).				
	CF	Wiseman, E. H. et al.; Arzneimittel-Forsch./Drug Res. 26, No. 7, pp. 1300-1303 (1976).				
	CG	Caira, Mino R. et al.; J. Chem. Soc., Chem. Commun., pp. 1061-1062 (1994).				
	CH	Escandar, G. M., Analyst, No. 124, pp. 587-591 (1999).				
	CI	Bordner, Jon et al.; Acta Cryst., C40, pp. 989-990 (1984).				
	CJ	Hong, Seok Cheon et al.; 33(2), 85-89 (2003), Chemical Abstract.				
	CK	Fenyvesi, E. et al.; Journal of Inclusion Phenomena and Macrocyclic Chemistry, Vol. 33, pp. 339-344 (1999).				
	CL	Jung, J. et al.; Journal of Supercritical Fluids, 20, pp. 179-219 (2001).				
	CM	Subramaniam, B. et al., Journal of Pharm. Sciences, Vol. 86, No. 8, pp. 885-890 (1997).				
	CN	Vrečer, F. et al., International Journal of Pharmaceutics, 68, pp. 35-41 (1991).				
/J.L.L./	CO	Barillaro, V. et al.; Proceeding of 7th Intl. Cyclodextrins Symposium, pp. 414-418 (1994).				

Examiner Signature	/Jonathan Law/	Date Considered	04/04/2008
--------------------	----------------	-----------------	------------

Birch, Stewart, Kolasch & Birch, LLP

MAA.bmp